The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zhukova I.A.

Siberian State Medical University, Tomsk

Kolupaeva E.S.

Siberian State Medical University, Tomsk, Russia

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Parkinson disease and asthenic syndrome

Authors:

Zhukova I.A., Kolupaeva E.S., Zhukova N.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(11): 60‑63

DOI: 10.17116/jnevro201811811160

Read: 4038 times

Download PDF (RU)
Contact the author
Table of contents

PARKINSON DISEASE AND ASTHENIC SYNDROME
PARKINSON DISEASE AND ASTHENIC SYNDROME

To cite this article:

Zhukova IA, Kolupaeva ES, Zhukova NG. Parkinson disease and asthenic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(11):60‑63. (In Russ.)
https://doi.org/10.17116/jnevro201811811160

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
The technology of indu­ction of physiological keto­sis in asthenia of various origins and decreased resi­stance to cognitive and physical acti­vity. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):48-54
The rela­tionship between inflammatory markers, fati­gue, and effort-based deci­sion-making in patients at clinical high risk for psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):85-91
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Evaluation of blepharoplasty outcomes using psychometric scales. Plastic Surgery and Aesthetic Medi­cine. 2024;(4-2):72-79
Effi­ciency of complex medi­cal reha­bilitation after pulmonary enda­rterectomy. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):629-636
Simu­ltaneous auto­plastic repair and diastasis recti correction for linea alba hernias. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):34-39
Abstract:

Objective. To study the clinical heterogeneity of fatigue syndrome and evaluate the efficacy of cytoflavin as an addition to standard treatment in patients with Parkinson’s disease. Material and methods. One hundred patients with Parkinson’s disease and fatigue took part in the study, 59 patients continued to participate in the study including 59.3% (32) women and 40.7% (27) men. All patients received standard treatment. The equivalent daily dose of levodopa (LEDD) was 736.9±419.1 mg/day. The average age of patients was 67±8.6 (from 65 to 85 years). Cytoflavin was used as an additional therapy in the standard dosage. All patients underwent neuropsychological examination for an estimate of the rate of fatigue, depression, health status, activity, mood and quality of life. Results and conclusion. Cytoflavin is well tolerated by patients with Parkinson’s disease and fatigue syndrome at the standard dosage. It improves the health, mood, quality of life and reduces fatigue.

Keywords:

Parkinson’s disease
non-motor symptoms
fatigue
quality of life

Authors:

Zhukova I.A.

Siberian State Medical University, Tomsk

Kolupaeva E.S.

Siberian State Medical University, Tomsk, Russia

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Close metadata

References:

  1. Titova N, Chaudhuri KR. Non-motor Parkinson disease: new concepts and personalisedmanagement. The Medical Journal of Australia. 2018;208(9):404-409. https://doi.org/10.5694/mja17.00993
  2. Nassif DV, Pereira JS. Fatigue in Parkinson’s disease: concepts and clinical approach. Psychogeriatrics: The Official Journal of the Japanese Psychogeriatric Society. 2018;18(2):143-150. https://doi.org/10.1111/psyg.12302
  3. Beiske AG, Loge JH, Heirmastaad MJ, Svensson E. Fatigue in Parkinson’s disease: prevalence and associated factors. Mov Disord. 2010;25:2456-2460. https://doi.org/10.1002/mds.23372
  4. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD; PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641-1649. https://doi.org/10.1002/mds.22643
  5. Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord. 2010;25:805-822. https://doi.org/10.1002/mds.22989
  6. Finsterer J, Mahjoub SZ. Fatigue in healthy and diseased individuals. Am J Hosp Palliat Care. 2013;3:562-575. https://doi.org/10.1177/1049909113494748
  7. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25:2493-2500. https://doi.org/10.1002/mds.23394
  8. Miwa H, Miwa T. Fatigue in patients with Parkinson’s disease: impact on quality of Life. Intern Med. 2011;50(15):1553-1558. https://doi.org/10.2169/internalmedicine.50.4954
  9. Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson’s disease. J Neurol Sci. 2011;310(1-2):12-16. https://doi.org/10.1016/j.jns.2011.05.006
  10. Dogan VB, Koksal A, Dirican A, Baybas S, Dirican A, Dogan GB. Independent effect of fatigue on health-related quality of life in patients with idiopathic Parkinson’s disease. Neurol Sci. 2015;36(12):2221-2226. https://doi.org/10.1007/s10072-015-2340-9
  11. Song W, Guo X, Chen K, Chen X, Cao B, Wei Q, Huang R, Zhao B, Wu Y, Shang HF. The impact of non-motor symptoms on the Health-Related Quality of Life of Parkinson’s disease patients from Southwest China. Parkinsonism Relat Disord. 2014;20(2):149-152. https://doi.org/10.1016/j.parkreldis.2013.10.005
  12. Zesiewicz TA, Patel-Larson A, Hauser RA, Sullivan KL. Social Security Disability Insurance (SSDI) in Parkinson’s disease. Disabil Rehabil. 2007;29(24):1934-1936. https://doi.org/10.1080/09638280701257247
  13. Hagell P, Brundin L. Towards an understanding of fatigue in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80(5):489-492. https://doi.org/10.1136/jnnp.2008.159772
  14. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008;71(7):481-485. https://doi.org/10.1212/01.wnl.0000324862.29733.69
  15. Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G. Interventions for fatigue in Parkinson’s disease. Cochrane Database Syst Rev. 2015; 10(10):CD010925. https://doi.org/10.1002/14651858.cd010925.pub2
  16. Moon HE, Paek SH. Mitochondrial Dysfunction in Parkinson’s Disease. Exp Neurobiol. 2015;24(2):103-116. https://doi.org/10.5607/en.2015.24.2.103
  17. Spinazzi M, Casarin A, Pertegato V, Salviati L, Angelini C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc. 2012;7:1235-1246. https://doi.org/10.1038/nprot.2012.058
  18. Hindle JV. Ageing, neurodegeneration and Parkinson’s disease. Age Ageing. 2010;39:156-161. https://doi.org/10.1093/ageing/afp223
  19. Vyortkin AL, Knorring GYu. Neuroprotective therapy: Meet — the drug Cytoflavin. Ambulatornyj Priem. 2016;2(3-6):14-18. (In Russ.)
  20. Gudkova AN, Osinovskaya NA, Polunina AG, Guekht AB. Investigation of the effects of cytoflavin on symptoms of depression and autonomic dysfunction in patients with organic depressive disorder. Lechenie Nervnih i Hronicheskih Zabolevaniy. 2013;12:50-55. (In Russ.)
  21. International statistical classification of diseases and health-related problems. Tenth revision. Geneva. 1995;1(1):698.
  22. Fahn S, Tolosa E, Marín C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, ed. Parkinson’s Disease and Movement Disorders. 2nd ed. Baltimore: Williams & Wilkin; 1993.
  23. Fahn S, Elton RL, Marsden CD, Calne DB, Lieberman A. Unified Parkinson’s Disease Rating Scale. Macmillan Health Care Information. 1987;143:153-163.
  24. Hoehn M, Jahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
  25. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-379.
  26. Meer B, Baker JA. The Stockton Geriatric Rating Scale. Journal of Gerontology. 1966;21(3):392-403.
  27. Sciolla A, Patterson TL, Wetherell JL, McAdams LA, Jeste DV. Functioning and well-being of middle-aged and older patients with schizophrenia: measurement with the 36-item short-form (SF-36) health survey. Am J Geriatr Psychiatry. 2003;11(6):629-637.
  28. Barkanova OV. Methods of diagnostics of emotional sphere: psychological workshop (series: library of actual psychology). Vol. 2. Krasnoyarsk: Litera-print; 2009 (In Russ.)
  29. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research. 1995;39(3):315-325.
  30. Prokhorov AO. Workshop on psychology of States. textbook. SPb.: Speech; 2004 (In Russ.)
  31. Sayutina SB, Shprah VV, Rozhkova NYu. Citicoline in combined treatment of parkinson’s disease. Pacific Medical Journal. 2013;4:76-78. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.